Welcome to our dedicated page for China Pharma news (Ticker: CPHI), a resource for investors and traders seeking the latest updates and insights on China Pharma stock.
China Pharma Holdings, Inc. reports developments tied to its specialty pharmaceutical business in China, where it develops, manufactures, and markets products for cardiovascular, central nervous system, infectious, and digestive diseases. News commonly centers on its wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., product portfolio updates, NMPA-related approvals, and dosage forms that include tablets, capsules, injectables, oral solutions, and other pharmaceutical products.
Company updates also cover the dry eye disease therapeutic device, completed generic-drug consistency evaluation for candesartan tablets, financing arrangements, convertible-note redemptions, and common-stock reverse splits. These announcements connect operating product activity with capital-structure actions for CPHI's NYSE American-listed common stock.
China Pharma Holdings, Inc. (CPHI) reported a 17.6% revenue decline to $2.0 million for Q3 2021, down from $2.4 million in Q3 2020. This drop is attributed to national drug price reductions. The net loss decreased to $0.8 million, compared to $1.0 million a year ago, primarily due to lower selling expenses. For the nine months ended September 30, 2021, revenue was $6.8 million, also down from $7.9 million in 2020, with a net loss of $2.4 million. The company remains optimistic about growth opportunities in specialty pharma and TCM amid favorable policies.
China Pharma Holdings, Inc. (CPHI) reported a 35.9% decline in revenue to $2.4 million for Q2 2021, compared to $3.8 million in Q2 2020, primarily due to a one-time sale of COVID-19 testers in the previous year. The company incurred a net loss of $0.8 million, a drop from a net income of $0.01 million in the same period last year. However, excluding this one-time deal, sales increased 15% year-over-year. The company has repaid a significant loan, reducing future cash flow pressures. Overall, CPHI remains optimistic about opportunities in specialty pharmaceuticals and Traditional Chinese Medicine.
China Pharma Holdings, Inc. (NYSE American: CPHI) announced that its Candesartan hypertension product successfully passed bioequivalence tests. The company intends to leverage these results to apply for National Medical Products Administration (NMPA) approval in China. Chairman and CEO Zhilin Li emphasized the significant demand for Candesartan, given hypertension's global health impact. The product aims to help control high blood pressure, which affects over a billion people worldwide and is a leading cause of death. A successful NMPA approval could enhance market reach and sales opportunities for the company.
China Pharma Holdings, Inc. (NYSE American: CPHI) announced plans to launch a highly purified NMN+PQQ product after a successful pilot scale test. NMN, a derivative of niacin, is believed to improve health by replenishing NAD+ levels that decline with age, potentially aiding cardiovascular function and wellness. CEO Zhilin Li emphasized the product's alignment with their healthcare category and market demand, indicating that it could enhance revenue stability. The company plans to leverage the Hainan Free Trade Port for sales and may seek partnerships for global distribution.
China Pharma Holdings, Inc. (NYSE American: CPHI) reported a 33.7% increase in revenue to $2.4 million for Q1 2021, up from $1.8 million a year earlier, primarily due to recovery from COVID-19 and favorable exchange rates. The company achieved a gross margin of 11.6%, slightly up from 11.0% in Q1 2020. However, the net loss widened to $0.8 million due to increased R&D investments. The company's CEO highlighted optimism for growth driven by a diversified product portfolio and upcoming product launches in compliance with Hainan Free Trade Port policies.
China Pharma Holdings, Inc. (CPHI) has responded to new policy measures supporting the Hainan Free Trade Port. These measures include the establishment of an e-prescription center and increased access for market drugs, expected to stimulate company growth. On April 17, 2021, they signed an agreement with Huiyi, an Internet hospital with over 40,000 registered doctors, to leverage the policy changes. The reforms also aim to attract investment and enhance medical tourism, projecting significant financial benefits for China Pharma, with potential market access worth up to 100 billion yuan by 2022.
China Pharma Holdings, Inc. (CPHI) reported fiscal year 2020 results with revenue of $10.9 million, unchanged from 2019. The gross margin improved to 18.0% from 13.6%, while loss from operations decreased significantly to $2.6 million versus $20.4 million in 2019. Net loss also improved to $2.9 million, equating to $0.07 per share. The company highlights a one-time revenue boost from COVID-19 testers totaling $1.7 million. Despite challenges, particularly from the pandemic, China Pharma aims to bolster healthcare product development and maintain financial sustainability.
China Pharma Holdings, Inc. (CPHI) announced its Q3 2020 financial results, reporting revenue of $2.4 million, unchanged from Q3 2019. Gross margin plunged to 2.0% from 15.7% year-over-year, with a net loss of $1.0 million compared to $0.7 million in the prior year. The operational loss also increased to $1.0 million. For the nine months ending September 30, 2020, total revenue stayed at $7.9 million, with a reduced net loss of $1.7 million versus $2.0 million in 2019. The decrease in net loss was aided by a foreign trade deal involving COVID-19 testers.
China Pharma Holdings, Inc. (NYSE American: CPHI) announced that its subsidiary, Hainan Helpson Medicine & Biotechniqe Co., Ltd., has received multiple certifications for its masks. These include the Disposable Medical Mask, Particle Filtering Half Mask, and KN95 Particulate Respirator, all meeting international filtration standards. The masks, produced in GMP-certified facilities, are now available for sale on the e-commerce platform 1688.com. This initiative supports global COVID-19 prevention efforts by providing high-quality masks to various markets.
China Pharma Holdings, Inc. (CPHI) reported a 46.8% revenue increase to $3.8 million for Q2 2020, driven primarily by a one-time sale of COVID-19 testers contributing $1.7 million. Gross margin improved to 30.5% from 6.4% year-over-year, while the company achieved an operating income of $0.1 million, compared to a loss of $0.8 million in the same quarter of 2019. Despite positive growth, net income was minimal at $0.01 million, as prior drug sales were affected by the COVID-19 outbreak. Cash and equivalents stood at $1.8 million, up from $1.1 million.